These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26384300)

  • 1. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.
    Miekus K; Lukasiewicz E; Jarocha D; Sekula M; Drabik G; Majka M
    Cell Death Dis; 2013 Jan; 4(1):e459. PubMed ID: 23328666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.
    Jaaks P; D'Alessandro V; Grob N; Büel S; Hajdin K; Schäfer BW; Bernasconi M
    PLoS One; 2016; 11(8):e0161396. PubMed ID: 27548722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling.
    Lukasiewicz E; Miekus K; Kijowski J; Drabik G; Wilusz M; Bobis-Wozowicz S; Majka M
    Folia Histochem Cytobiol; 2009 Jan; 47(3):485-9. PubMed ID: 20164036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.
    Singh S; Vinson C; Gurley CM; Nolen GT; Beggs ML; Nagarajan R; Wagner EF; Parham DM; Peterson CA
    Am J Pathol; 2010 Oct; 177(4):2055-66. PubMed ID: 20829439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells.
    Otabe O; Kikuchi K; Tsuchiya K; Katsumi Y; Yagyu S; Miyachi M; Iehara T; Hosoi H
    Oncol Rep; 2017 Jan; 37(1):98-104. PubMed ID: 27840956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
    Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
    Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
    Jankowski K; Kucia M; Wysoczynski M; Reca R; Zhao D; Trzyna E; Trent J; Peiper S; Zembala M; Ratajczak J; Houghton P; Janowska-Wieczorek A; Ratajczak MZ
    Cancer Res; 2003 Nov; 63(22):7926-35. PubMed ID: 14633723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
    Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
    Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.
    Skrzypek K; Kusienicka A; Trzyna E; Szewczyk B; Ulman A; Konieczny P; Adamus T; Badyra B; Kortylewski M; Majka M
    Cell Death Dis; 2018 May; 9(6):643. PubMed ID: 29844345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
    Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
    Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
    Saini M; Verma A; Mathew SJ
    Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
    Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
    J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications.
    Wysoczynski M; Shin DM; Kucia M; Ratajczak MZ
    Int J Cancer; 2010 Jan; 126(2):371-81. PubMed ID: 19588509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.
    Kuda M; Kohashi K; Yamada Y; Maekawa A; Kinoshita Y; Nakatsura T; Iwamoto Y; Taguchi T; Oda Y
    Tumour Biol; 2016 Apr; 37(4):5213-23. PubMed ID: 26553361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/β-catenin signalling pathway.
    Ge C; Wu S; Wang W; Liu Z; Zhang J; Wang Z; Li R; Zhang Z; Li Z; Dong S; Wang Y; Xue Y; Yang J; Tan Q; Wang Z; Song X
    Oncotarget; 2015 May; 6(13):10964-77. PubMed ID: 25844602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
    Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
    Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
    Belyea BC; Naini S; Bentley RC; Linardic CM
    Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma.
    Dräger J; Simon-Keller K; Pukrop T; Klemm F; Wilting J; Sticht C; Dittmann K; Schulz M; Leuschner I; Marx A; Hahn H
    Oncotarget; 2017 Jan; 8(2):3259-3273. PubMed ID: 27965462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.